You just read:

Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for ixazomib, First and Only Once-Weekly Oral Proteasome Inhibitor for Multiple Myeloma

News provided by

Takeda Pharmaceutical Company Limited

Dec 06, 2015, 11:00 ET